Effects of C5 Complement Inhibitor Pexelizumab on Outcome in High-Risk Coronary Artery Bypass Grafting: Combined Results From the PRIMO-CABG I and II Trials

Study Questions:

What is the safety and efficacy of terminal complement inhibition in reducing perioperative myocardial infarction (MI) and mortality in patients undergoing coronary artery bypass graft (CABG) surgery who have two or more predefined preoperative risk factors?